Trial Profile

Phase I clinical trial of OC134 for Eye Disorders

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OC 134 (Primary)
Indications Allergic conjunctivitis; Eye disorders
Focus Adverse reactions
Acronyms SUNLIGHT

Most Recent Events

13 Mar 2025 New trial record
10 Mar 2025 According to Nanomerics media release company has completed 28 consecutive days of administration in its OC134 trial and discharged the last volunteer from the trial. And is pleased to report that the trial met its primary endpoints.
28 Feb 2025 According to Virpax Pharmaceuticals media release, the study completed in January 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com